UK markets closed
  • NIKKEI 225

    27,999.96
    -249.28 (-0.88%)
     
  • HANG SENG

    20,003.44
    -42.33 (-0.21%)
     
  • CRUDE OIL

    90.54
    -0.22 (-0.24%)
     
  • GOLD FUTURES

    1,810.50
    +5.30 (+0.29%)
     
  • DOW

    32,774.41
    -58.13 (-0.18%)
     
  • BTC-GBP

    19,189.06
    -726.09 (-3.65%)
     
  • CMC Crypto 200

    537.23
    -20.12 (-3.61%)
     
  • ^IXIC

    12,493.93
    -150.53 (-1.19%)
     
  • ^FTAS

    4,129.39
    -3.43 (-0.08%)
     

2022 World Pharmacovigilance Conference - 2 Day Online Conference - November 22-23, 2022

·4-min read
Company Logo
Company Logo

Dublin, Aug. 02, 2022 (GLOBE NEWSWIRE) -- The "Pharmacovigilance World 2022" conference has been added to ResearchAndMarkets.com's offering.

With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug.

However, evidence suggests though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading cause of mortality.

The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use. Pharmacovigilance brief the potential implications of such trends on the evolution of the science.

However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales, and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc.

The Pharmacovigilance World 2022 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug Safety, and how it contributes to public health. It will also allow all its participants to interact with the experts, and discuss the various developments, challenges faced, and innovations in the field.

The conference will bring forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.

Conference Streams Include

  • Global PV & Methodologies

  • Data management & Analytics in PV

  • PV Automation, AI & Machine Learning

  • Safety Signals & Management

  • Pharmacovigilance Regulations

  • Risk Management

  • Patient Centric Drug Safety

  • Case Management

  • Quality & Compliance

  • Pharmacovigilance Outsourcing

  • Medical Devices Safety

  • Adverse Drug Reactions

Key Discussions

  • Pharmacovigilance and globalization

  • Pharmacovigilance in a pandemic world

  • Women and child health care medicines and pharmacovigilance

  • Patient-centric approaches in PV

  • Pharmacovigilance legislation and regulations

  • Harmonization and pharmacovigilance

  • Advanced therapeutic techniques and pharmacovigilance

  • Pharmacovigilance and data management and eudravigilance

  • Post-marketing surveillance in pharmacovigilance

  • PV regulations and challenges

  • Benefit-risk management strategies

  • Risk management and minimization

  • Risk Evaluation and Mitigation

  • Adverse drug reactions reporting

  • Signal detection and post-authorization safety

  • Good Pharmacovigilance Practices

  • Innovative approaches to drug safety

  • Strategies to improve PV

  • Real-World Evidence in PV

  • Big data and AI in pharmacovigilance

  • Pharmacovigilance Workflows with AI & Automation

  • Other emerging technologies in PV

Speakers Include:

  • Robert Massouh, Director - Risk Management Product Lead, Pfizer

  • Robert Di Giovanni, Global Project Safety Lead, Novartis

  • Raj K Bhogal, Senior Director, R&D Audits & Inspections, Jazz Pharmaceuticals

  • Rodrigo Ruiz, Senior Manager, Patient Safety, Bristol-Myers Squibb

  • Ajinkya Inamdar, Director, Vaccines Global Safety Strategy and Risk Management, The Janssen Pharmaceutical Companies of Johnson & Johnson

  • Maria Maddalena Lino, Safety risk Lead Director, Pfizer

  • Michael Von Forstner, Global Head of Clinical Safety and Pharmacovigilance, Biogen

  • Laura Arce Mora, Country Safety Lead, Pfizer

  • Maria De Los Angeles Hernandez Loli, Patient Safety Lead Cluster Ecuador - Peru, Boehringer Ingelheim

  • Valentina Mancini, Director Pharmacovigilance, EU and UK QPPV, Shionogi

  • Victoria Bartasek, Senior Associate Director, Global Pharmacovigilance Operations, Boehringer Ingelheim

For more information about this conference visit https://www.researchandmarkets.com/r/om47w

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting